arrow
R

R. Coleman Lindsley

Harvard University
H指数:43
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Derivation of a blood count-based machine learning model to prioritise sequencing for high-risk clonal haematopoiesis: a retrospective cohort study

基于血细胞计数推导的机器学习模型以优先考虑高风险克隆性造血的测序:一项回顾性队列研究

2026-09-220
OAAI
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex

骨髓增生异常综合征及前体状态在种族、族裔和性别方面的临床、遗传和病理学变异

2026-03-290
OAAI
Exposure to Agent Orange and Association with Myelodysplastic Syndromes

暴露于橙剂及其与骨髓增生异常综合征的关联

2026-03-020
OA
Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing

突变SRSF2相关的红细胞生成障碍是由FYN剪接错误导致的mTORC1信号增强所定义。

Leukemia
IF13.4
2026-02-260
PRE
A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study

《MDS自然病史研究中定义MDS及前体髓系疾病进展的一种新方法》

2026-02-130
OAAI
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial

在关键性随机试验中,CPX-351选择性地使AML和脊髓发育不良相关突变患者受益

2026-02-040
OAAI
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

异基因移植前急性髓系白血病中可测量的残留突变NPM1

2025-11-240
OAAI
ZRSR2 loss causes aberrant splicing in JAK2V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression

ZRSR2缺失导致JAK2V617F驱动的骨髓增殖性肿瘤中发生异常剪接,但不足以驱动疾病进展。

2025-09-160
OAAI
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome

durvalumab单药治疗或联合tremelimumab加或不加阿扎胞苷治疗骨髓增生异常综合征患者的1期研究

2025-03-010
OAAI
Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

骨髓增生异常综合征在MDS自然史研究(MDS NHS)中的进展

BLOOD
IF23.1
2024-11-050
PRE
Author Correction: Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 (Vol 22, 288, 2016)

作者更正: Rps14单倍不足导致S100A8和S100A9介导的类红细胞分化阻滞 (第22卷,288,2016)

2024-10-230
OA
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
2024-09-131
OAAI
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes
LEUKEMIA
IF13.4
2024-07-201
OAAI
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study
2024-05-152
PRE